See more : STMicroelectronics N.V. (STMMI.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Emergent Health Corp (EMGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emergent Health Corp, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hisamitsu Pharmaceutical Co., Inc. (HTSUF) Income Statement Analysis – Financial Results
- Liberty Latin America Ltd. (LILA) Income Statement Analysis – Financial Results
- Mountain Province Diamonds Inc. (0V7X.L) Income Statement Analysis – Financial Results
- Jiangsu Allfavor Intelligent Circuits Technology CO.,Ltd (300964.SZ) Income Statement Analysis – Financial Results
- Andhra Cements Limited (ANDHRACEMT.NS) Income Statement Analysis – Financial Results
Emergent Health Corp (EMGE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.emergenthealthcorp.com
About Emergent Health Corp
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally. Emergent Health Corp. is based in King of Prussia, Pennsylvania. As of August 26, 2014, Emergent Health Corp was taken private.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.64M | 574.61K | 119.57K | 167.19K | 183.12K | 989.84K | 1.37K |
| Cost of Revenue | 596.87K | 446.97K | 60.09K | 45.77K | 54.47K | 260.79K | 563.45 |
| Gross Profit | 1.04M | 127.64K | 59.48K | 121.42K | 128.65K | 729.04K | 802.30 |
| Gross Profit Ratio | 63.49% | 22.21% | 49.74% | 72.62% | 70.26% | 73.65% | 58.74% |
| Research & Development | 27.57K | 8.59K | 2.09K | 1.60K | 9.66K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 155.11K | 46.56K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 53.77K | 63.94K | 0.00 | 0.00 | 0.00 |
| SG&A | 2.42M | 1.88M | 256.96K | 175.80K | 177.74K | 539.86K | 576.83 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.45M | 1.88M | 259.05K | 201.16K | 187.39K | 539.86K | 576.83 |
| Cost & Expenses | 3.04M | 2.33M | 319.14K | 246.93K | 241.86K | 800.65K | 1.14K |
| Interest Income | 0.00 | 8.75K | 87.67 | 0.00 | 0.00 | 1.84 | 13.83 |
| Interest Expense | 220.13K | 361.53K | 0.00 | 0.00 | 9.83K | 0.00 | 0.00 |
| Depreciation & Amortization | 20.00K | 20.00K | 20.00K | 20.00K | 10.00K | 352.00 | 0.35 |
| EBITDA | -1.39M | -1.73M | -179.57K | -55.98K | -48.74K | 189.54K | 225.82 |
| EBITDA Ratio | -84.88% | -302.13% | -150.18% | -33.48% | -26.62% | 19.15% | 16.53% |
| Operating Income | -1.41M | -1.76M | -199.57K | -75.98K | -58.74K | 189.19K | 225.47 |
| Operating Income Ratio | -86.10% | -305.61% | -166.91% | -45.45% | -32.08% | 19.11% | 16.51% |
| Total Other Income/Expenses | -220.14K | -352.78K | -90.28K | 0.00 | -9.83K | 1.84K | -13.83 |
| Income Before Tax | -1.63M | -2.11M | -289.85K | -79.74K | -68.57K | 191.03K | 211.64 |
| Income Before Tax Ratio | -99.57% | -367.00% | -242.41% | -47.69% | -37.44% | 19.30% | 15.50% |
| Income Tax Expense | 108.00 | -1.39K | -1.08 | -0.62 | -1.07K | 70.00K | 80.00 |
| Net Income | -1.63M | -2.11M | -288.76K | -79.13K | -67.50K | 121.03K | 131.64 |
| Net Income Ratio | -99.57% | -366.76% | -241.51% | -47.33% | -36.86% | 12.23% | 9.64% |
| EPS | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
| Weighted Avg Shares Out | 402.97M | 260.85M | 58.10M | 58.05M | 56.46M | 24.80M | 24.84K |
| Weighted Avg Shares Out (Dil) | 402.97M | 260.85M | 58.10M | 79.93M | 56.46M | 24.80M | 24.80K |
Apollo Biowellness, Inc./Resonate Blends, Inc., Provides Corporate Update Following Closing of Share Exchange Agreement
Resonate Blends Executes a Share Exchange Agreement With Emergent Health Corp.
Source: https://incomestatements.info
Category: Stock Reports